Coleman and Slomovitz Continue the Discussion on Maintenance PARP Inhibition in Ovarian Cancer
In our exclusive interview, Robert L. Coleman, MD, FACOG, FACS and Brian M. Slomovitz, MD, discussed the benefits and limitations of PARP inhibition in all-comers with newly diagnosed advanced ovarian cancer and pivotal PARP inhibitor trials in the frontline setting.
Welcome to a very special edition of OncLive® On Air! I’m your host today, Caroline Seymour.
OncLive® On Air is a podcast from OncLive, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, sponsored by GlaxoSmithKline, we passed the mic to Robert L. Coleman, MD, FACOG, FACS, chief scientific officer of The US Oncology Network, and Brian M. Slomovitz, MD, a gynecologic oncologist at Broward Health and a professor of obstetrics and gynecology at Herbert Wertheim College of Medicine, who provided perspective on the advantages and potential drawbacks of using PARP inhibitors as frontline maintenance therapy in all-comers with newly diagnosed advanced ovarian cancer.
To that end, we flipped a coin to determine who would argue for PARP therapy versus against PARP therapy. As such, the views and opinions expressed herein do not necessarily reflect those of the faculty or their affiliates.
In our exclusive interview, Dr. Coleman and Dr. Slomovitz discussed the benefits and limitations of PARP inhibition in all-comers with newly diagnosed advanced ovarian cancer and pivotal PARP inhibitor trials in the frontline setting.
Sponsored by:
